

Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol

Neasa Mc Gettigan ,^{1,2} Marion Hanley,³ Fiona Skelly,^{4,5} Jennifer Dowling,⁶ Ruth Dunne,³ Martina M Morrin,³ Noel McCaffrey,⁷ Aoibhlinn O'Toole,^{1,2} Karen Boland ^{1,2}

To cite: Mc Gettigan N, Hanley M, Skelly F, *et al.* Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol. *BMJ Open Gastro* 2022;**9**:e000959. doi:10.1136/bmjgast-2022-000959

Received 11 May 2022
Accepted 26 July 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Neasa Mc Gettigan;
neasamcgettigan21@rcsi.com

ABSTRACT

Introduction Biologic and small-molecule therapies have revolutionised the treatment of moderate-to-severe inflammatory bowel disease (IBD). A significant proportion of patients experience early or delayed treatment failure. Patients with IBD with greater visceral obesity are less likely to respond to biologics. Sarcopenia has been identified as a predictor of disease severity and need for rescue therapy in acute severe ulcerative colitis. The aim of this study is to assess the feasibility of a physician-derived exercise programme in patients with IBD commencing biologic or small-molecule therapy in addition to the effect on physical fitness, body composition and objective measures of quality of life, fatigue scores and disease activity.

Methods and analysis This is a randomised controlled feasibility study comparing the effects of a physician-derived exercise programme and standard medical care (biologic/small-molecule therapy) with standard care alone in patients with moderate to severe IBD. Patients with IBD in the intervention group will undergo a structured exercise programme for 20 weeks. Both IBD groups will carry out body composition, disease activity and quality-of-life assessments at baseline, week 12 and week 26. The primary objective is to assess the feasibility of the physician-derived exercise programme in patients with IBD commencing disease-modifying therapies. Secondary endpoints include a change in cardiorespiratory fitness, disease activity/inflammation, fatigue, health-related quality of life outcomes and body composition between the two IBD groups. Exploratory endpoints include validation of anterior thigh ultrasound for sarcopenia screening, assessment of proinflammatory cytokines and markers of immunometabolism.

Ethics and dissemination This study has received ethical approval from the Beaumont Hospital Ethics committee on 22 October 2021 (reference number 21/21). Data generated or analysed during this study will be published as an article and supplementary appendix in

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Exercise is safe in patients with mild to moderate inflammatory bowel disease (IBD). Sarcopenia is common in patients with IBD and present in over 40% of patients. Anterior thigh ultrasound (US) has been validated for sarcopenia screening in rheumatoid arthritis to detect low muscle mass.

WHAT THIS STUDY ADDS

⇒ This study is the first of its kind to enrol patients with IBD with severely active disease commencing disease-modifying therapies to a supervised exercise programme. It aims to examine the immunometabolic response to exercise in patients with IBD and to validate thigh US as an early predictor of low muscle mass in patients with IBD.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This study will provide evidence for the wider introduction of a prescribed exercise programme in the management of patients with IBD with moderate-severe disease activity. It will validate anterior thigh US as a readily available screening tool for early sarcopenia detection in IBD and provide insight into modulation of immunometabolic pathways by supervised exercise.

relevant medical journals. The data will also be presented at national and international conferences.

Trial registration number NCT05174754.

INTRODUCTION

Biologic (monoclonal antibodies) and small-molecule therapies have revolutionised the treatment of moderate-to-severe inflammatory bowel disease (IBD) and are frequently



used as first-line therapy in moderate-to-severe IBD.¹⁻³ Despite significant advances in IBD therapeutics, a significant proportion of patients experiences a primary or secondary loss of response to treatment.^{4,5}

In keeping with temporal trends, 20–30% of patients with IBD are obese and previous data have shown that patients with IBD with greater visceral obesity are less likely to respond to biologics, have worse outcomes including postoperative complications and are at greater risk of other chronic diseases.⁶⁻⁸ Adipocytes exposed to intestinal microbiota that permeate a compromised intestinal epithelial barrier produce proinflammatory and anti-inflammatory cytokines, some of which attract macrophages, which in turn produce proinflammatory cytokines, including interleukin (IL)-6 and tumour necrosis factor (TNF)- α .⁹⁻¹¹

Lean muscle mass is also compromised in chronic inflammatory states. Rates of sarcopenia are high in patients with IBD despite improvements in pharmacological treatments.¹² Sarcopenia is classically associated with older persons and is characterised by both a loss of skeletal muscle mass and function.¹³ Low muscle mass and strength (sarcopenia) have been identified as a predictor of disease severity and need for rescue therapy in acute severe ulcerative colitis (UC).¹⁴ Myopenia (muscle wasting) has been shown to be associated with primary loss of response to anti-TNF therapy in patients with Crohn's disease (CD).¹⁵ Anterior thigh US for the detection of the early loss of muscle mass as part of sarcopenia screening has been recently validated in rheumatoid arthritis.¹⁶ Regional loss of muscle mass may occur earlier than total muscle loss; therefore, the use of anterior thigh US may detect low muscle mass earlier than conventional imaging (CT, MRI, bioelectrical impedance analysis (BIA) or dual energy X-ray absorptiometry (DEXA)).¹⁷

Current evidence suggests that exercise exhibits an anti-inflammatory effect through the induction of anti-inflammatory cytokines, predominantly mediated by IL-6 released from skeletal muscle during exercise, which, has inhibitory effects on TNF- α production.^{18,19} Alteration in metabolism is also a key component to the pathogenesis of IBD and an increasing volume of studies have shown the effect of metabolism on regulating immune cells. Exercise is recognised to regulate metabolism and is a promising adjunctive therapy for management of autoimmune disorders through modulation of immunometabolic pathways, achieving an anti-inflammatory state while also enhancing well-being among subjects.²⁰ Few studies examining exercise in IBD have assessed effects on validated IBD activity markers or inflammatory biomarkers. Those studies have shown an increase in fitness, bone mineral density and a decrease in IBD-related induced stress and anxiety.²¹ One randomised study measured proinflammatory cytokines before and after prescribed exercise did not see a significant difference in cytokine levels, likely as a result of patients recruited being in clinical remission.²²

The type of exercise interventions previously studied in IBD varies from moderate-intensity aerobic and resistance training (the majority of studies) to walking, running, yoga and high intensity interval training.²²⁻²⁴ Limited studies have previously shown that moderate-intensity combined aerobic and resistance training is safe in unfit patients with IBD with quiescent disease and can quickly achieve favourable body changes without adverse effects.²² A previous pilot study examining in adults with CD during a 17-month period found no serious exercise-related adverse events and had a high completion rate of 89–97%.²³

ExWell Medical is a novel community-based exercise programme for individuals with chronic disease in Ireland. It offers group exercise classes with medical oversight for people with a range of chronic diseases, including cardiovascular disease, pulmonary disease, diabetes and cancer. The programme is a significant resource for healthcare professionals and individuals living with chronic disease and hosts approximately 700 participant visits per week.^{25,26}

The design of this study aims to investigate the feasibility and impact of an adjuvant intervention in the form of a community-based physician-delivered and supervised exercise programme in combination with best medical therapy in patients with active IBD. We hypothesise that the physician-derived exercise programme may be associated with synergistic induction of an anti-inflammatory response with alteration of immunometabolic pathways and cytokine response. To our knowledge, there are no published studies investigating the effect of a physician-derived exercise programme on patients with active moderate-severe IBD commencing biologic or small-molecule therapy.

METHODS AND ANALYSIS

Study objectives

The primary objective is to assess the feasibility of the physician-derived exercise programme in patients with IBD commencing disease-modifying therapies including:

- ▶ The recruitment, retention and adherence rates in both IBD arms.
- ▶ The frequency and nature of adverse events.
- ▶ Potential barriers to exercise in patients with moderate-severe disease.

Secondary objectives

1. To demonstrate that the exercise programme will result in a clinically significant increase in cardiorespiratory fitness (15% improvement in 6min walk test (6-MWT)) when compared with standard medical care alone.
2. To assess disease-related outcomes attributed to the exercise programme:
 - Improved response to induction with biologic or small molecule therapy.
 - Improved overall disease control/inflammation.

- Changes in body composition.
- Changes in hand-grip strength.
- Changes in health-related quality of life (HRQoL).
- Changes in fatigue score.

Exploratory endpoints

- ▶ To estimate the response of proinflammatory cytokines to the prescribed exercise programme and the effect of prescribed exercise on markers of immunometabolic pathways.
- ▶ To validate the use of anterior thigh ultrasound (US) as an imaging modality to detect the presence of early loss of muscle mass and subsequent response to exercise.
- ▶ To carryout subgroup analysis looking at the difference in inflammatory response and body composition in patients with CD versus UC.

Study design

The study is a single-centre three-arm prospective randomised non-blinded controlled feasibility study of the impact and feasibility of a physician-accredited 20-week exercise programme in patients attending a tertiary IBD referral centre in Ireland with active IBD undergoing induction therapy. Eligible patients with IBD will be recruited 1:1 to exercise intervention plus standard medical care or standard care with medical therapy alone. The investigators will recruit a third group of healthy controls for comparison of baseline body composition and inflammatory markers. The flow of the study is seen in figure 1. The study has been registered with Clinicaltrials.gov. The Standard Protocol Items: Recommendations for Interventional Trials checklist was followed when developing the study protocol.




Figure 1 Study flow diagram. BIA, bioelectrical impedance analysis; BMI, body mass index; CDAI, Crohn’s Disease Activity Index; HBI, Harvey-Bradshaw Index; IBDQ, Inflammatory Bowel Disease Questionnaire; 6-MWT, 6-minute walk test; US, ultrasound, PIL- patient information leaflet.

**Table 1** Participant inclusion and exclusion criteria.

Eligibility criteria	Exclusion criteria
Age \geq 18 years	Age $<$ 18 years
Confirmed moderate to severe IBD based on endoscopic evaluation (Mayo endoscopic sub-score $>$ 2, Simple Endoscopic Score for Crohn's disease (SES-CD) $>$ 7), clinical scoring tools (Crohn's Disease Activity Index (CDAI) $>$ 220, Harvey-Bradshaw Index (HBI) $>$ 8, partial Mayo score \geq 5) and faecal calprotectin ($>$ 250 μ g/g).	Inactive or mild IBD.
Must be able to provide written informed consent and complete questionnaires.	Inability to participate in the exercise programme (unable to perform 6-minute walk test (6-MWT), unable to attend for assessment of parameters at any time point).
Must be physically able to complete an exercise programme.	An uncontrolled cardiovascular condition such as unstable angina, uncontrolled cardiac arrhythmias, uncontrolled symptomatic heart failure or symptomatic severe aortic stenosis. A significant musculoskeletal condition, neurological condition, mental illness or intellectual disability that restricts participation in a physical exercise programme.
Previous biologic or small molecule therapy use.	Pregnant women.
	Healthy controls will be excluded if they have a history of underlying inflammatory conditions.
IBD, inflammatory bowel disease.	

Patient and public involvement

Patients with IBD at two sites (Beaumont Hospital and Connolly Hospital) were surveyed to identify the need for an exercise programme based on physical activity levels, barriers to exercise and willingness to participate in the programme once available. Patients attending outpatient clinics, infusion suites and admitted with disease flares were asked to participate. The survey included specific binary questions asking (1) whether patients would avail of personalised exercise advice and (2) whether they would be interested in participating in a physician-supervised exercise programme. Patients responded favourably, with 75% indicating their interest in participating in a supervised exercise programme.

Study setting and population

The study is being carried out in the Department of Gastroenterology, Beaumont Hospital and is sponsored by the Royal College of Surgeons in Ireland, Dublin (RCSI). Eligible participants will be identified from the IBD clinic and inpatient ward (table 1). A diagnosis of moderate-severe IBD will be confirmed (by endoscopic evaluation and/or faecal calprotectin). Blinding of patients, data collectors and physiological assessors is not possible due to the nature of the study. The intention-to-treat principle will be followed.

Trial subjects

Intervention arm: IBD participants enrolled in the study who are randomised to the intervention arm will be referred to ExWell Medical to part take in a 20-week community-based exercise programme (described below). IBD participants in the intervention arm will receive best

medical therapy in addition to the exercise programme. Measurements of physical fitness, anthropometrics, body composition, thigh US, blood sampling and questionnaires will be carried out at baseline, 12 and 26 weeks (table 2).

IBD control arm: IBD participants who are randomised to the standard of care group will receive best medical therapy and will be advised to continue their usual level of physical activity. Measurements of physical fitness, anthropometrics, body composition, thigh US, blood sampling and questionnaires will be carried out at baseline, 12 and 26 weeks (table 2).

Healthy control arm: a third group of healthy controls attending for elective endoscopic colonic polyp surveillance will be recruited for comparison of baseline body composition and inflammatory measurements. Patients will undergo once-off anthropometrics, body composition, thigh US, blood sampling and questionnaires.

Exercise protocol

The ExWell Medical programme will offer both an in-person and virtual format (via the Zoom platform) for recruited patients. Patients randomised to the exercise plus standard medical therapy arm will be asked to participate for 20 weeks and will be invited to continue to participate beyond this period if they wish. This programme caters to each patient's physical fitness and ability with a focus on developing sustainable exercise habits to positively impact long-term health. Participants will complete an induction to the programme, which involves (1) information on the programme purpose, structure and logistics, (2) baseline assessments and (3) a brief demonstration of an exercise class.

Table 2 Outline of outcome measurement assessment time points for patients with IBD

Timepoint	Enrolment	Allocation	Post enrolment		Post intervention
	$-t_1$	0	t_1 Week 1	t_2 Week 12	t_3 Week 26
Enrolment:					
Eligibility screen	X				
Informed consent	X				
(7-day accelerometer)	X				
IPAQ-SF	X				
Allocation		X			
Interventions:					
Exercise and standard medical care			←—————→		
Standard medical care			x	x	x
Healthy controls			↔		
Assessments					
Physical fitness: 6MWT			x	x	x
BIA			x	x	x
Anterior thigh US			x	x	x
Clinical response: HBI, CDAI, pMayo			x	x	x
Inflammatory response			x	x	x
Endoscopy response			x	x	x
Grip strength			x	x	x
Sit-to-stand			x	x	x
Quality of life: SIBDQ			x	x	x
Fatigue: FSS			x	x	x
Dietary patterns			x	x	x
CDAI, Crohn's Disease Activity Index; FSS, fatigue severity scale; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; IPAQ-SF, International Physical Activity Questionnaire- Short Form; 6MWT, 6-minute walk test; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; US, ultrasound.					

The ExWell Medical exercise intervention is described subsequently using the frequency, intensity, time, type principle (figure 2).^{25 26}

1. Frequency

Participants will be advised to attend ≥ 3 supervised group exercise classes per week and encouraged to attend the same classes every week to foster social support and habit formation.

2. Intensity

For the aerobic component of the exercise classes, participants will be instructed to work at an intensity at which they 'feel moderately breathless, have a red face and sweat'. For the resistance component of the exercise classes, participants aim to achieve 15–20 repetitions at resistance that feel 'tough' at each station.

3. Time

The class includes a 5–7 min warm-up followed by a 30 min exercise training phase and a 5 min cool down. The 5 min warm-up will be followed by 10 min of aerobic exercises followed by 10 min of circuit-based resistance

exercises, 10 min of balance/core exercise and a 5 min cool down.

4. Type

The aerobic component of the exercise classes will involve body weight exercises including jumping jacks and high knees. Resistance training will involve circuit-based exercises that include upper and lower body exercises using body weight resistance, dumbbells or household weighted objects. Balance/core exercises will include single leg standing exercises and seated core exercising using a chair. The cool down will consist of low-intensity aerobics and range of motion exercises and stretching (table 1). Adherence to the programme will be monitored as the number of sessions attended.

Outcome measurements

Baseline physical activity assessments

1. The validated WHO International Physical Activity Questionnaire short form will be used to determine participants' most recent physical activity patterns prior to randomisation. It is a self-reported or




Figure 2 Exercise protocol by fitness, intensity, time, type (FITT principle).

telephone-administered questionnaire that details the participants physical activity in the previous 7 days.^{27 28}

- Accelerometers will be worn at baseline for 7 days prior to randomisation of participants. Axivity AX3 monitors will be assigned to patients to wear on their non-dominant hand and the AX3 OMGUI Configuration and Analysis Tool will be used to analyse the recorded data.²⁹

Continuous physical assessment

- 6-MWT: participants will be instructed to cover as much distance as possible in 6 min while walking, running or a combination, back and forth on a flat indoor 30m course. Participants will receive a standard set of instructions adapted from the American Thoracic Society guidelines for the 6-MWT. No warm-up will be permitted. The position on the 30 m course at which the participant stops at the end of the 6th minute will be marked with a cone and the distance covered in the final partial lap will be measured to the nearest metre using a measuring tape. The total distance covered will be recorded.³⁰

Disease activity

- Physicians will complete validated disease-specific symptom scores including the Harvey-Bradshaw index and the Crohn's Disease Activity Index for patients with CD and a partial Mayo score for patients with UC.^{31–34}

- Blood markers of inflammation-c-reactive protein (CRP), serum albumin and platelets in addition to full blood count, renal, bone and liver profiles.
- Stool markers of inflammation-faecal calprotectin.^{35 36}
- Endoscopic evaluation will be performed at baseline and at 26 weeks to determine endoscopic response as per current standard of care including intestinal mucosal biopsies.

Body composition analysis and assessment of sarcopenia Muscle strength and function

- Hand-grip strength: measured using both arms with a hand-held dynamometer (Jamar 5030J1 Hydraulic Hand Dynamometer). Patients are sitting on a chair with a back support with their shoulder abducted and neutrally rotated. The angle of the elbow is at 90° and the feet are flat on the floor. The average of three attempts will be recorded for both arms.
 - Sit-to-stand test: participants sit on a chair with arms crossed, feet flat on the floor parallel to each other, approximately one shoulder width apart. They then stand up and sit down for five repetitions as quickly as possible and are asked to extend their legs on each stand. The time taken to perform five repetitions is timed.³⁷
- Other: 25–0-hour vitamin D: low levels of vitamin D have been shown to be associated with the presence of

sarcopenia and a reduction in muscle strength.^{38 39} We aim to measure vitamin D levels at baseline (for all three groups) and at 12 and 26 weeks for patients with IBD.

Muscle mass measurements and body composition analysis

1. Anthropometrics: height and body mass measurements will be carried out using a stadiometer and electronic scale (model 707 balance scales: Seca GmbH, Hamburg, Germany). Body mass index calculated as body mass in kilograms divided by squared height in metres. Waist and hip circumferences will be taken using a tape measure.
2. BIA: will be carried out on all patients with IBD (at baseline, 12 weeks and 26 weeks) to determine skeletal muscle mass (kg), body fat % and visceral adiposity (kg). It will also be carried out on healthy controls. The Seca 525 mBCA medical body composition analyser with Seca analytics 115 will be used by the investigators.⁴⁰ BIA readings will be used to calculate cut-off values using receiver operating characteristic (ROC) curve analysis for anterior thigh muscle measurements from anterior thigh ultrasound imaging and to validate the findings of anterior thigh muscle US.^{16 41}
3. Anterior thigh muscle ultrasound: will be carried out to measure thigh muscle thickness (MT) as a surrogate for muscle mass. Participants will be in the supine position on the examination table, with the legs extended in a relaxed position. B-mode ultrasound will be used (US LOGIQ emachine 12L, MSK probe setting and a frequency range of 7-12MHz). The anterior superior iliac spine (ASIS) will be palpated as a landmark. Using a measuring tape, the midpoint from the superior border of the patella to the ASIS will be identified and marked with a surgical pen as the main reference point. Measurements will be taken from the right leg, the most common dominant side. The ultrasound probe will be gently set in transverse plane on the anterior thigh, over the region of the quadriceps muscle group with appropriate amount of ultrasound gel to create a good acoustic window. The probe will be carefully set on the thigh so that it will not directly touch the skin to push the soft tissue. MT is defined as the distance between the anterior fascia of the rectus femoris muscle and the posterior fascia of the vastus intermedius muscle. US measurements will be carried out by a senior physician specifically trained in anterior thigh ultrasound or by a senior radiology trainee, for the purpose of this study.^{16 41 42}

Health-related outcomes (QOL, fatigue scores)

1. The Short Inflammatory Bowel Disease Questionnaire is a HRQoL tool measuring physical, social and emotional status (score 10–70, poor to good HRQoL). Ten items are included in the questionnaire, all scores are reported with a 7-point scale (1=poor HRQoL, 7=optimum HRQoL) and scores from each item are summed to produce a total score.⁴³

2. The fatigue severity scale (FSS): FSS is a unidimensional instrument, which includes nine items, with a score of 1–7 for each item. The FSS total score is the mean score of the nine items and a higher FSS score indicates greater fatigue. Significant fatigue has previously been defined using a cut-off FSS score of 3 or 4.^{44–46}

Exploratory outcomes

Markers of immunometabolism

Whole blood will be collected and stored at -80°C for subsequent flow cytometry using cryogenic vials and cytodexics whole blood stabiliser (1:1 dilution of stabiliser with blood per vial). Flow cytometry will be performed to analyse peripheral blood mononuclear cells including macrophages and lymphocyte subsets, which include T helper cells (CD4^+ , CD8^+). Prototypic markers of cellular activation and metabolism, nitric oxide, arginase-1 and arginase-2 will also be assessed by flow cytometry.

Circulating proinflammatory cytokines and adipokines

Blood samples will be prepared prior to running an ELISA: venous blood will be drawn using Sarstedt serum clot activator tubes and centrifuged as per manufacturer's instructions. Isolated serum will be aliquoted into coded centrifuge tubes in volumes of $500\ \mu\text{L}$ per tube and immediately frozen at -80°C . Serum cytokine analysis will be carried out, which will include the measurement of serum IL1-Beta, IL-6, IL-8, IL-10, IL-17, IL-23, sTNFR1 and adiponectin using a custom AssayGenie Multiplex ELISA assay as per the manufacturer's instructions by flow cytometry. Serum leptin, ghrelin and $\text{TNF}\alpha$ will each be measured using separate single ELISA kit assays as per the manufacturer's instructions.

Sample size calculation and randomisation process

Sample size

As this is a feasibility study, no formal sample size calculation was performed. This study follows sample size recommendations for feasibility/pilot randomised controlled trials. We aim to recruit 25 participants to each IBD group and 20 healthy controls (ie, total sample size of 70), which follows the Sim and Lewis rule of thumb for pilot study sample size calculation of >50 patients.⁴⁷

This number of participants is deemed adequate to provide sufficient information on important feasibility issues such as recruitment, retention and acceptability of the exercise programmes.

Randomisation process

Randomisation is to be carried out using computer-generated sequencing. Sealed envelopes will be used until interventions are allocated. Participants will be randomised in a 1:1 fashion to the exercise programme plus standard of care or standard of care alone. It will not be possible to blind patients to their intervention allocation given the nature of the intervention.

Data collection, management and analysis

Data collection methods and retention

Informed consent and data at the three time points will be organised and collected by a physician carrying out a full-time research degree. Agreed appointment times for completion of all measures will be agreed with participants. Data will be retained for 5 years post-publication.

Data management

Data will be collected on paper case report forms and de-identified. All patients screened for the trial will be assigned a unique participant ID number. A Data Monitoring Committee consisting of two clinicians and an assigned data manager to ensure the validity of the data during the study has been established. Data will be regularly examined for missing and impossible values. The principal investigators will have access to the final data set along with the full-time research clinician. Anonymous patient data may be shared on request. Site visits will be carried out by the sponsor (RCSI) and annual updates will be provided to the Beaumont Ethics Committee.

Statistical analysis

Statistical analysis will be performed using Stata and Minitab. Feasibility will be evaluated by calculating the percentage of people approached who participate in the intervention (recruitment) and the percentage who complete the intervention (retention and adherence). Given the small number of participants, interim analysis for efficacy will not be carried out.

Descriptive statistics will be used to describe the study population and parameters at baseline. Changes in biomarkers will be assessed using Student *t* tests or the Mann-Whitney *U* test depending on the distribution of the data. Clinical outcomes will be analysed as between-group differences using analysis of variance (ANOVA) adjusted for baseline and stratification factors and multivariate analysis with Lasso regression used to study associations with improvement in symptoms, muscle mass or outcomes. Mixed linear regression models will be used to examine QoL outcomes. ROC curves and areas under the curve will be used to determine the cut-off values for sarcopenia using anterior thigh muscle ultrasound measurements and BIA muscle mass measurements.

Ethics and dissemination

Ethical approval

This study has received ethical approval from the Beaumont Hospital Ethics committee on the 22 October 2021 (reference number 21/21). Informed written consent will be obtained from all participants.

Data dissemination and data sharing

Data dissemination and data sharing will be prioritised at the end of the study period, all data generated or analysed during this study will be published as an article and supplementary appendix in relevant medical journals. Any changes to the protocol will be

updated on clinicaltrials.gov and ethics amendments will be sought where necessary.

Safety reporting

All adverse events will be recorded from the beginning of the study up until the final time point at the 26-week assessment. A designated co-investigator has been identified as the responsible party for reviewing adverse events reported and subsequent determination of the significance, relationship to the intervention and seriousness of the adverse events. Reporting of adverse events will be carried out in accordance with the Royal College of Physicians reporting procedures (sponsoring body). Patients will continue to be monitored in the IBD clinic postcessation of the study and in the rare event that the patient is harmed in any way during the study they are covered by clinical trial insurance and medical indemnity.

DISCUSSION

This study is designed to address the feasibility of an exercise programme in patients with IBD with moderate-to-severe disease undergoing induction with disease-modifying therapies. The potential benefits of exercise as an adjunctive therapy along with the safety of an exercise programme in patients with IBD with severe disease will be explored. In addition to the impact on patient-related outcomes such as fatigue, luminal symptoms and quality of life, we intend to analyse objective metrics, including the impact on serum proinflammatory cytokine profiles and immunometabolic panels to add to current knowledge, while providing evidence-based advice to patients.

Exercise has been shown to be a promising therapeutic intervention to influence metabolism in autoimmune disorders including multiple sclerosis through regulation of immune cells. This is mediated through cytokine secretion, and modulation of metabolic regulators including tryptophan.²⁰ Alteration in metabolism is also a key component to the pathogenesis of IBD and there may be a role of prescribed exercise in modulating metabolic pathways in patients with IBD.

The use of anterior thigh US to measure MT as a surrogate marker of early loss of muscle mass is a novel concept in patients with IBD but has been used effectively in other inflammatory conditions such as rheumatoid arthritis.^{16 42} US is a convenient, non-ionising and cost-effective imaging modality compared with CT and MRI and can be performed at the bedside.

In conclusion, this study will examine if a physician-derived exercise programme is feasible, safe, improves physical fitness, disease control, response to medical therapy, body composition and quality of life in patients with moderate-severe IBD. Novel aspects of this study are the inclusion of patients with active moderate-to-severe IBD, examining the response to

disease-modifying therapies as a secondary endpoint and the use of anterior thigh US to detect early loss of muscle mass. This study will provide evidence for the wider introduction of a prescribed exercise programme in the management of patients with IBD with moderate–severe disease activity.

Author affiliations

- ¹Department of Gastroenterology, Beaumont Hospital, Dublin, Ireland
²Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
³Department of Radiology, Beaumont Hospital, Dublin, Ireland
⁴Department of Sport and Health Sciences, Technological University of the Shannon (TUS), Westmeath, Ireland
⁵Sports and Health Sciences, ExWell Medical, Dublin, Ireland
⁶Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
⁷School of Health and Performance, ExWell Medical, Dublin City University, Dublin, Ireland

Twitter Karen Boland @karenjboland

Acknowledgements The authors would like to thank the inflammatory bowel disease nurses in Beaumont Hospital and the infusion unit in St Joseph's Raheny for their support with the project. The authors would also like to thank the Physiotherapy department in the RCSI for their input and support.

Contributors NMG: wrote the paper, project conception, final approval. MH: critical revisions, ultrasound technique conception, final approval. FS: critical revisions, exercise programme conception, final approval. RD: radiology advisor, final approval. MM: radiology advisor, ultrasound technique conception, final approval. JD: scientific advisor, critical revisions, final approval. NM: designed the exercise programme, final approval. AO'T: project conception, critical revisions, final approval. KB: project conception, critical revisions, final approval.

Funding The project has received seed funding from Royal College of Surgeons Ireland (RCSI) 2021 (grant number N/A), Dublin and from the Strategic Academic Recruitment programme (StAR) MD RCSI/Beacon Hospital grant (21218A01). Additional funding was received from Janssen for IBD patient-related research 2020 (grant number-N/A).

Competing interests KB received funding from Janssen for the support of this study.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data generated or analysed during this study will be published as an article and supplementary appendix in relevant medical journals.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Neasa Mc Gettigan <http://orcid.org/0000-0001-5744-0435>

Karen Boland <http://orcid.org/0000-0003-2327-9924>

REFERENCES

- Stidham RW, Lee TCH, Higgins PDR, *et al.* Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. *Aliment Pharmacol Ther* 2014;39:1349–62.
- Cholapranee A, Hazlewood GS, Kaplan GG, *et al.* Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. *Aliment Pharmacol Ther* 2017;45:1291–302.
- Lohan C, Diamantopoulos A, LeReun C, *et al.* Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. *BMJ Open Gastroenterol* 2019;6:e000302.
- Gisbert JP, Marin AC, McNicholl AG, *et al.* Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. *Aliment Pharmacol Ther* 2015;41:613–23.
- Singh S, George J, Boland BS, *et al.* Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. *J Crohns Colitis* 2018;12:635–43.
- Harper JW, Zisman TL. Interaction of obesity and inflammatory bowel disease. *World J Gastroenterol* 2016;22:7868–81.
- Bryant RV, Schultz CG, Ooi S, *et al.* Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life. *Inflamm Bowel Dis* 2019;25:592–600.
- Ding Z, Wu X-R, Remer EM, *et al.* Association between high visceral fat area and postoperative complications in patients with Crohn's disease following primary surgery. *Colorectal Dis* 2016;18:163–72.
- Fink C, Karagiannides I, Bakirtzi K, *et al.* Adipose tissue and inflammatory bowel disease pathogenesis. *Inflamm Bowel Dis* 2012;18:1550–7.
- Kane H, Lynch L. Innate immune control of adipose tissue homeostasis. *Trends Immunol* 2019;40:857–72.
- Rowan CR, McManus J, Boland K, *et al.* Visceral adiposity and inflammatory bowel disease. *Int J Colorectal Dis* 2021;36:2305–19.
- Grillot J, D'Engremont C, Parmentier A-L, *et al.* Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's disease. *Clin Nutr* 2020;39:3024–30.
- Santilli V, Bernetti A, Mangone M, *et al.* Clinical definition of sarcopenia. *Clin Cases Miner Bone Metab* 2014;11:177–80.
- Cushing KC, Kordbacheh H, Gee MS, *et al.* Reply to 'Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients'. *J Crohns Colitis* 2018;12:1256–1041.
- Ding NS, Malietzis G, Lung PFC, *et al.* The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. *Aliment Pharmacol Ther* 2017;46:883–91.
- Tada M, Yamada Y, Mandai K, *et al.* Screening for sarcopenia and obesity by measuring thigh muscle and fat thickness by ultrasound in patients with rheumatoid arthritis. *Osteoporos Sarcopenia* 2021;7:81–7.
- Kara M, Kaymak B, Ata AM, *et al.* STAR-Sonographic thigh adjustment ratio: a golden formula for the diagnosis of sarcopenia. *Am J Phys Med Rehabil* 2020;99:902–8.
- Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. *Mediators Inflamm* 2008;2008:1–6.
- Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. *J Appl Physiol* 2005;98:1154–62.
- Afzal R, Dowling JK, McCoy CE. Impact of exercise on Immunometabolism in multiple sclerosis. *J Clin Med* 2020;9:3038.
- Eckert KG, Abbasi-Neureither I, Köppel M, *et al.* Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications. *BMC Gastroenterol* 2019;19:115.
- Cronin O, Barton W, Moran C, *et al.* Moderate-Intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent inflammatory bowel disease: a randomized controlled cross-over trial. *BMC Gastroenterol* 2019;19:29.
- Tew GA, Leighton D, Carpenter R, *et al.* High-Intensity interval training and moderate-intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial. *BMC Gastroenterol* 2019;19:19.
- Baker KA, Miller TD, Marino FE, *et al.* The exercise-induced inflammatory response in inflammatory bowel disease: a systematic review and meta-analysis. *PLoS One* 2022;17:e0262534.
- Kehoe B, Skelly F, Moyna N, *et al.* The effect of participating in MedEx wellness, a community-based chronic disease exercise rehabilitation programme, on physical, clinical and psychological health: a study protocol for a cohort trial. *Contemp Clin Trials Commun* 2020;19:100591.
- Tully R, Loughney L, Bolger J, *et al.* The effect of a pre- and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (the PERIOP-OG trial): study protocol for a randomised controlled trial. *Trials* 2020;21:638.

- 27 Cleland C, Ferguson S, Ellis G, *et al.* Validity of the International physical activity questionnaire (IPAQ) for assessing moderate-to-vigorous physical activity and sedentary behaviour of older adults in the United Kingdom. *BMC Med Res Methodol* 2018;18:176.
- 28 Craig CL, Marshall AL, Sjörström M, *et al.* International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* 2003;35:1381–95.
- 29 Doherty A, Jackson D, Hammerla N, *et al.* Large scale population assessment of physical activity using wrist worn Accelerometers: the UK Biobank study. *PLoS One* 2017;12:e0169649.
- 30 Puente-Maestu L. Physiological rationale of commonly used clinical exercise tests. *Pulmonology* 2020;26:159–65.
- 31 Best WR, Beckett JM, Singleton JW, *et al.* Development of a Crohn's disease activity index. National cooperative Crohn's disease study. *Gastroenterology* 1976;70:439–44.
- 32 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987;317:1625–9.
- 33 Vermeire S, Loftus EV, Colombel J-F, *et al.* Long-Term efficacy of Vedolizumab for Crohn's disease. *J Crohns Colitis* 2017;11:412–24.
- 34 de Jong MJ, Huibregtse R, Masclee AAM, *et al.* Patient-Reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review. *Clin Gastroenterol Hepatol* 2018;16:648–63.
- 35 Manceau H, Chicha-Cattoir V, Puy H, *et al.* Fecal calprotectin in inflammatory bowel diseases: update and perspectives. *Clin Chem Lab Med* 2017;55:474–83.
- 36 Schoepfer AM, Beglinger C, Straumann A, *et al.* Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. *Inflamm Bowel Dis* 2013;19:332–41.
- 37 Netz Y, Ayalon M, Dunsky A, *et al.* 'The Multiple-Sit-to-Stand' Field Test for Older Adults: What Does It Measure? *Gerontology* 2004;50:121–6.
- 38 Visser M, Deeg DJH, Lips P, *et al.* Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study Amsterdam. *J Clin Endocrinol Metab* 2003;88:5766–72.
- 39 Mastaglia SR, Seijo M, Muzio D, *et al.* Effect of vitamin D nutritional status on muscle function and strength in healthy women aged over sixty-five years. *J Nutr Health Aging* 2011;15:349–54.
- 40 Bony-Westphal A, Jensen B, Braun W, *et al.* Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices. *Eur J Clin Nutr* 2017;71:1061–7.
- 41 Hida T, Ando K, Kobayashi K, *et al.* < Editors' Choice > ultrasound measurement of thigh muscle thickness for assessment of sarcopenia. *Nagoya J Med Sci* 2018;80:519–27.
- 42 Smerilli G, Cipolletta E, Tanimura S, *et al.* Ultrasound measurement of muscle thickness at the anterior thigh level in rheumatology setting: a reliability study. *Clin Rheumatol* 2021;40:1055–60.
- 43 Jowett SL, Seal CJ, Barton JR, *et al.* The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. *Am J Gastroenterol* 2001;96:2921–8.
- 44 Grimstad T, Norheim KB, Isaksen K, *et al.* Fatigue in newly diagnosed inflammatory bowel disease. *J Crohns Colitis* 2015;9:725–30.
- 45 Krupp LB, LaRocca NG, Muir-Nash J, *et al.* The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;46:1121–3.
- 46 Schreiner P, Rossel J-B, Biedermann L, *et al.* Fatigue in inflammatory bowel disease and its impact on daily activities. *Aliment Pharmacol Ther* 2021;53:138–49.
- 47 Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. *J Clin Epidemiol* 2012;65:301–8.